Orphan Drugs and Rare Diseases Conference 2018

SMi Group17 - 18 October, London, UK.
Patients with rare diseases cannot continue to be overlooked because of costly therapies and have the same rights to treatment as any other patient. At this year's Orphan Drugs and Rare Diseases conference, organised by SMi Group and taking place in London, industry experts will address the opportunities and challenges within the rare disease treatment field.

Keep up to date with the industry and to learn from expert speaker panel, bringing you important new case studies and reports on this year’s relevant topics.

Highlights in 2018

  • Discuss the pricing and reimbursement of orphan drugs
  • Understand the challenges of patient recruitment and patient-centric research
  • Hear the MHRA's perspective on benefit-risk assessment in rare diseases
  • Explore the clinical development of orphan drugs for rare disease
  • Gain insight into potential synergies between regulators and assessors

Speakers include

  • Carina Schey, Researcher, University of Groningen
  • Xavier Ortega, Project Manager, Rare Diseases, Minoryx
  • Nigel Nicholls, Director and Country Manager UK/Ireland, BioMarin Europe Ltd
  • Yolanda Barbachano, Senior Statistical Assessor, MHRA
  • MichaleBouskila-Chubb, Head of Business Development, Healx

Interactive Workshop (16 October) run by JG Zebra Consulting will be looking into question: "Working together for HTA in rare diseases - a step too far or the way forward?"

Orphan Drugs and Rare Diseases conference this year is set to inspire the international rare diseases community by exploring synergies between regulators, health and technology assessors

For further details, please visit:
http://www.orphandrugs.co.uk

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...